Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > ARCHIVE
ARCHIVE
- The Reporter's Eye: 3
April 11, 2005
- MPC Adds SP Codes to All Its Ethical Drugs
April 11, 2005
- Astellas Sets Out with 2,500 MRs in Japan
April 11, 2005
- OTC/HEALTH FOOD NEWS IN BRIEF
April 11, 2005
- Eisai Carries Out Organizational Restructuring
April 11, 2005
- NEW PRODUCYS
April 11, 2005
- Toho to Tie Up with 6 Regional Wholesalers
April 11, 2005
- Average Foreign Price Adjustment Rule Comes Under Criticism Again
April 11, 2005
- IMS to Boost Consulting Business to 20% of Sales
April 11, 2005
- Schering-Plough KK Aims for Sales of \100 Bil. by FY2010
April 11, 2005
- BUSINESS NEWS IN BRIEF
April 11, 2005
- NEW PRODUCYS
April 11, 2005
- Janssen Pharm. Posts Strong Growth in 2004
April 4, 2005
- BI Extends Collaboration with MorphoSys AG
April 4, 2005
- Meiji Yakuhin Completes New Contract Mfg Plant
April 4, 2005
- Alfresa HD Aims at Sales of \1,385 Bil. in 2008
April 4, 2005
- Korosho to Start Major Studies on Diabetes and Depression
April 4, 2005
- No Big Increase in Business with Sankyo in Near Term: Mediceo
April 4, 2005
- RESEARCH & DEVELOPMENT NEWS IN BRIEF
April 4, 2005
- BUSINESS NEWS IN BRIEF
April 4, 2005
ページ
Japan is ramping up its push to spread regional formularies nationwide, a policy expected to standardize treatments, strengthen supply resilience,…
We had just gotten off a call with a client in Europe, and we’d received a bit of an earful. “Philip,” the client pressed, “what can this candidate bring to us? We know what he does, but what has he…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…